Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Coltene Holding AG's revenue per share for the
six
months ended in Jun. 2026 was CHF18.94.
Coltene Holding AG's revenue per share for the trailing twelve months (TTM) ended in Jun. 2026 was CHF39.47.
Warning Sign:
Coltene Holding AG revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue Per Share Growth Rate of Coltene Holding AG was -1.90% per year.
During the past 3 years, the average Revenue Per Share Growth Rate was -3.50% per year.
During the past 5 years, the average Revenue Per Share Growth Rate was -1.70% per year.
During the past 10 years, the average Revenue Per Share Growth Rate was 0.90% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Coltene Holding AG's Revenue per Share or its related term are showing as below:
XSWX:CLTN'
s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -12.2 Med: 0.4 Max: 6.3
Current: -3.5
During the past 13 years, Coltene Holding AG's highest 3-Year average Revenue Per Share Growth Rate was 6.30% per year. The lowest was -12.20% per year. And the median was 0.40% per year.
XSWX:CLTN's 3-Year Revenue Growth Rate is ranked worse than 66.53% of 756
companies
in the Medical Devices & Instruments industry
Industry Median: 3.7
vs XSWX:CLTN: -3.50
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Coltene Holding AG Revenue per Share Related Terms
Coltene Holding AG Revenue per Share Historical Data
* Premium members only.
The historical data trend for Coltene Holding AG's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:CLTN vs ISRG, BDX, MDLN: Revenue per Share Comparison
For the Medical Instruments & Supplies subindustry, Coltene Holding AG's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Coltene Holding AG PS Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Coltene Holding AG's PS Ratio distribution charts can be found below:
* The bar in red indicates where Coltene Holding AG's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Coltene Holding AG's Revenue Per Share for the fiscal year that ended in Dec. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was CHF39.47
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Coltene Holding AG (XSWX:CLTN) has a Revenue per Share of CHF39.47 as of Jun. 2026. Revenue per share equals the per-share value of a company's sales. View historical data on Coltene Holding AG and its competitors. According to the industry distribution chart, Coltene Holding AG ranks #503 out of 756 companies in the Medical Devices & Instruments industry, placing it in the top 66.5%.
Is Coltene Holding AG's Revenue per Share too high?
Coltene Holding AG's current Revenue per Share is CHF39.47. Based on the distribution chart, Coltene Holding AG ranks #503 out of 756 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Coltene Holding AG has a GF Score™ of 69/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Coltene Holding AG's Revenue per Share compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Coltene Holding AG ranks #503 out of 756 companies for Revenue per Share. This places Coltene Holding AG in the lower half of its industry. The industry median Revenue per Share is 3.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Medical Devices & Instruments company?
The median Revenue per Share among Medical Devices & Instruments companies is 3.70, based on 756 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Coltene Holding AG and its competitors. For the Medical Devices & Instruments industry, the median Revenue per Share is 3.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Coltene Holding AG's current Revenue per Share is CHF39.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Coltene Holding AG stock overvalued right now?
Based on GuruFocus' analysis, Coltene Holding AG (XSWX:CLTN) is currently considered Fairly Valued. The stock's GF Value™ is CHF51.28, compared to a current price of CHF48.75 — trading 4.9% below its estimated fair value. The current Revenue per Share is CHF39.47. Coltene Holding AG's overall GF Score™ is 69/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Coltene Holding AG (XSWX:CLTN), the current Revenue per Share is CHF39.47 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Coltene Holding AG (XSWX:CLTN) Overvalued in 2026?
Based on GuruFocus' analysis, Coltene Holding AG stock appears to be undervalued.
The current stock price of CHF48.75 is trading 4.9% below its estimated GF Value™ of CHF51.28.
GuruFocus considers Coltene Holding AG to be Fairly Valued.
Key valuation signals for XSWX:CLTN:
Revenue per Share: CHF39.47
GF Value™: CHF51.28 vs. price of CHF48.75 (4.9% below fair value)
No single metric tells the full story. See the XSWX:CLTN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Coltene Holding AG is a manufacturer and distributor of consumables and small devices for dental practices, dental service organisations (DSOs), dental clinics and laboratories, as well as for non-dental niches (e.g., clinics for ophthalmology or podiatry). The Group develops, manufactures, and sells mainly via distribution channels a broad and comprehensive range of disposables, tools, and equipment for dentists and dental laboratories. Geographically, it operates in EMEA, North America, Latin America, and Asia/Oceania, with maximum from North America.
69GF Score
Get the complete analysis for XSWX:CLTN
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:CLTN has been successfully added to your 
